Cargando…
Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma
Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic abil...
Autores principales: | Pu, Weilin, Geng, Xin, Chen, Sidi, Tan, Lixing, Tan, Yulong, Wang, An, Lu, Zhouyi, Guo, Shicheng, Chen, Xiaofeng, Wang, Jiucun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5166538/ https://www.ncbi.nlm.nih.gov/pubmed/27994665 http://dx.doi.org/10.7150/jca.15758 |
Ejemplares similares
-
Quantitative assessment of the diagnostic role of FHIT promoter methylation in non-small cell lung cancer
por: Geng, Xin, et al.
Publicado: (2016) -
Genome-Wide DNA Methylation Profiles Reveal Common Epigenetic Patterns of Interferon-Related Genes in Multiple Autoimmune Diseases
por: Chen, Sidi, et al.
Publicado: (2019) -
Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer
por: Guo, Shicheng, et al.
Publicado: (2014) -
Targeted bisulfite sequencing identified a panel of DNA methylation-based biomarkers for esophageal squamous cell carcinoma (ESCC)
por: Pu, Weilin, et al.
Publicado: (2017) -
Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients
por: Abudukadeer, Abida, et al.
Publicado: (2012)